TIMP1 and laryngotracheoesophageal cleft: Incorporating objective clinical measures, such as inflammatory markers (e.g., TIMP-1) that can be triggered by HSV-1 [89] and neurocognitive tests, could improve the accuracy of symptom–microbiome associations and help contextualize immune responses in LC.